Cancer Family
Nervous System Neoplasm
CI-CAN-00000038Explore in graph →
Non-malignant1,523 active trials9 approved drugs210 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000038Explore in graph →
Clinical trials
5,873 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02658981 | Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) | completed | Phase 1 | 63 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT01491893 | PVSRIPO for Recurrent Glioblastoma (GBM)(PVSRIPO) | completed | Phase 1 | 61 | Istari Oncology, Inc.INDUSTRY | 1 | Sep 28, 2023 |
| clinicaltrials |
| NCT03158389 | NCT Neuro Master Match - N²M² (NOA-20)(N²M²) | completed | Phase 1 / Phase 2 | 228 | University Hospital HeidelbergOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT02095132 | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 76 | National Cancer Institute (NCI)NIH | 2 | Sep 26, 2023 | clinicaltrials |
| NCT02793466 | Durvalumab in Pediatric and Adolescent Patients | completed | Phase 1 | 15 | Leo MascarenhasOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT04119674 | Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 33 | Zhejiang Cancer HospitalOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT02386826 | INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme | completed | Phase 1 | 65 | SCRI Development Innovations, LLCOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03953131 | Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas | completed | Phase 1 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT00634231 | A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors | completed | Phase 1 | 8 | Candel Therapeutics, Inc.INDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT00751270 | Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas(BrTK01) | completed | Phase 1 | 15 | Candel Therapeutics, Inc.INDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT03009201 | Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery | completed | Phase 1 | 16 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 16, 2023 | clinicaltrials |
| NCT01419834 | Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors | completed | Phase 1 | 68 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT02619864 | mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme | completed | Phase 1 | 15 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT04456140 | Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study | completed | Phase 1 | 230 | Mayo ClinicOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT01713439 | Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALL(CYCHEALL) | completed | Phase 1 | 32 | Baylor College of MedicineOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT00876993 | Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors | completed | Phase 1 | 26 | Johns Hopkins All Children's HospitalOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT02022644 | Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma | completed | Phase 1 | 18 | University of California, San FranciscoOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT03726515 | CART-EGFRvIII + Pembrolizumab in GBM | completed | Phase 1 | 7 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02661282 | Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma | completed | Phase 1 / Phase 2 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT04757662 | Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma | completed | Phase 1 | 18 | Washington University School of MedicineOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT00584883 | A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 | 24 | University of Alabama at BirminghamOTHER | 1 | Jun 7, 2023 | clinicaltrials |
| NCT00662506 | Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2023 | clinicaltrials |
| NCT01081223 | Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma | completed | Phase 1 / Phase 2 | 12 | TVAX BiomedicalINDUSTRY | 1 | Jun 1, 2023 | clinicaltrials |
| NCT01257594 | EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas | completed | Phase 1 | 22 | Andrew B Lassman, MDOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT02238496 | Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas | completed | Phase 1 | 10 | Andrew B Lassman, MDOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT03236857 | A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies | completed | Phase 1 | 143 | AbbVieINDUSTRY | 8 | May 22, 2023 | clinicaltrials |
| NCT04091503 | Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma | completed | Phase 1 | 30 | Center Trials & Treatment EuropeNETWORK | 3 | Apr 25, 2023 | clinicaltrials |
| NCT02444546 | Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors | completed | Phase 1 | 6 | Mayo ClinicOTHER | 1 | Apr 24, 2023 | clinicaltrials |
| NCT03849105 | 131I-IPA and Concurrent XRT in Recurrent GBM(IPAX-1) | completed | Phase 1 / Phase 2 | 10 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 3 | Apr 14, 2023 | clinicaltrials |
| NCT04212793 | Detection of PitNET Tissue During TSS Using Bevacizumab-800CW(DEPARTURE) | completed | Phase 1 | 20 | University Medical Center GroningenOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT00005835 | N99-02: Melphalan and Buthionine Sulfoximine(BSO) | completed | Phase 1 | 31 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 2 | Apr 10, 2023 | clinicaltrials |
| NCT00084422 | N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma | completed | Phase 1 | 47 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 2 | Apr 10, 2023 | clinicaltrials |
| NCT00885326 | N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma | completed | Phase 1 | 29 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 2 | Apr 10, 2023 | clinicaltrials |
| NCT01019850 | N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma | completed | Phase 1 | 27 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT03086616 | CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glioma (DIPG) (PNOC 009) | completed | Phase 1 | 6 | Sabine Mueller, MD, PhDOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT03178032 | Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas | completed | Phase 1 | 12 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT04089449 | A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas | completed | Phase 1 | 86 | Prelude TherapeuticsINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT00639639 | Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme(ATTAC) | completed | Phase 1 | 42 | Gary Archer Ph.D.OTHER | 1 | Mar 13, 2023 | clinicaltrials |
| NCT04205357 | Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma(SAS-GKRS) | completed | Phase 1 | 24 | Haukeland University HospitalOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT01269424 | BG & TMZ Therapy of Glioblastoma Multiforme | completed | Phase 1 | 10 | Stanton Gerson MDOTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT01792310 | A Phase 1/2A Study of LAM561 in Adult Patients With Advanced Solid Tumours | completed | Phase 1 / Phase 2 | 54 | Laminar PharmaceuticalsINDUSTRY | 2 | Feb 21, 2023 | clinicaltrials |
| NCT02462629 | Study of BLZ-100 in Pediatric Subjects With CNS Tumors | completed | Phase 1 | 29 | Blaze Bioscience Inc.INDUSTRY | 1 | Feb 21, 2023 | clinicaltrials |
| NCT03867123 | A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients | completed | Phase 1 | 18 | Laminar PharmaceuticalsINDUSTRY | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04334863 | WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors | completed | Phase 1 | 10 | Emory UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT03072134 | Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma | completed | Phase 1 | 12 | Northwestern UniversityOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT02829931 | Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas | completed | Phase 1 | 33 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT04430842 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | completed | Phase 1 | 15 | Quadriga Biosciences, Inc.INDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT04657315 | Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients(MSC11FCD-GBM) | completed | Phase 1 / Phase 2 | 10 | CHA UniversityOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT03355794 | A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) | completed | Phase 1 | 19 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT03542773 | Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET | completed | Phase 1 | 38 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 11, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Oct 6, 2023source: clinicaltrials